MBX · Company research
MBX Biosciences, Inc. Common Stock (MBX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Learn Why The Bull Case For MBX Biosciences Stock Could Change Following Early Obesity Data - Simply Wall Street | Learn Why The Bull Case For MBX Biosciences Stock Could Change Following Early Obesity Data Simply Wall Street | View source ↗ | Simply Wall Street | Oct 17, 2026 | neutral | 0 | 0.6 |
| Analysts Offer Insights on NA Companies: X-Energy, Inc. Class A (XE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail | Analysts Offer Insights on NA Companies: X-Energy, Inc. Class A (XE) and MBX Biosciences, Inc. (MBX) The Globe and Mail | View source ↗ | The Globe and Mail | Oct 13, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (NASDAQ:MBX) Given New $84.00 Price Target at Stifel Nicolaus - MarketBeat | MBX Biosciences (NASDAQ:MBX) Given New $84.00 Price Target at Stifel Nicolaus MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Stifel raises MBX Biosciences price target to $84 on obesity drug data - Investing.com Canada | Stifel raises MBX Biosciences price target to $84 on obesity drug data Investing.com Canada | View source ↗ | Investing.com Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Average Price Target of $83.89 - MarketBeat | MBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Average Price Target of $83.89 MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Stifel raises MBX Biosciences price target to $84 on obesity drug data - Investing.com Nigeria | Stifel raises MBX Biosciences price target to $84 on obesity drug data Investing.com Nigeria | View source ↗ | Investing.com Nigeria | Oct 12, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (NasdaqGS:MBX) Stock Forecast & Analyst Predictions - Simply Wall Street | MBX Biosciences (NasdaqGS:MBX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run? - Yahoo Finance | Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257% - Yahoo Finance | MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257% Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Discipline and Rules-Based Execution in MBX Response - Stock Traders Daily | Discipline and Rules-Based Execution in MBX Response Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 8, 2026 | neutral | 0 | 0.6 |
| UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data - Investing.com | UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data Investing.com | View source ↗ | Investing.com | Sep 28, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (NASDAQ:MBX) Stock Jumps 4.1% - Time to Buy? - MarketBeat | MBX Biosciences (NASDAQ:MBX) Stock Jumps 4.1% - Time to Buy? MarketBeat | View source ↗ | MarketBeat | Sep 28, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX) - Seeking Alpha | MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 23, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - Simply Wall Street | MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 4, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan | MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| An MBX Biosciences obesity candidate showed 7% mean weight loss in 8 weeks - Stock Titan | An MBX Biosciences obesity candidate showed 7% mean weight loss in 8 weeks Stock Titan | View source ↗ | Stock Titan | Aug 6, 2026 | neutral | 0 | 0.6 |
| MBX Biosciences posts $37.1 million Q2 net loss - Quiver Quantitative | MBX Biosciences posts $37.1 million Q2 net loss Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| MBX Forecast — Price Target — Prediction for 2027 - TradingView | MBX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance | Insider Stock Buying Reaches US$1.06m On MBX Biosciences Yahoo Finance | View source ↗ | Yahoo Finance | May 15, 2026 | neutral | 0 | 0.6 |
| Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance | Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? Yahoo Finance | View source ↗ | Yahoo Finance | Apr 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.